Financing
Magnitude Biosciences Raises £1.3 Million to Scale Drug Screening in Living Worms
The Durham spinout is expanding VivoScan, an automated whole-worm screening platform. The funding supports scale, but promising worm results still need mammalian…
Longeveron Is Doing Another 1-for-10 Reverse Stock Split. Here’s Why That Matters.
Longeveron’s second 1-for-10 reverse split since 2024 can restore its share price mechanically. It cannot resolve runway, financing or clinical execution risk.
Astromech Raises $20 Million to Predict How Biology Changes
The Colossal Biosciences spinout is valued at a reported $3.8 billion as it builds AI models around evolutionary history. The financing is…
Life Biosciences Raises $80 Million as Reprogramming Enters the Clinic
The financing extends the company’s runway through its first human safety study. The valuation case still depends on safety, delivery and durable…